ClinicalTrials.gg
CompletedNCT00488618Updated Apr 14, 2017Results posted

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

A Phase 2 interventional study of Cariprazine (RGH-188) and Placebo in Bipolar Disorder, sponsored by Forest Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-14.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.

Enrollment
5th of 11
238 · median 234
Started
2007
the only one that year
Phase 2
6 of 11
1 open now
Registered
2nd of 11
by date

Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 5th largest by enrollment, is the only one that started in 2007, is one of 6 in phase 2, and was the 2nd registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bipolar Disorder by AbbVie, or all of them as a file.
02

Study summary

This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of two treatment groups: RGH-188 or placebo

03

Conditions studied

  • Bipolar Disorder

Keywords

  • Mania
  • Bipolar I Disorder
  • Acute Mania Associated with Bipolar I Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female inpatients 18 to 65 years of age
  • Meeting , Fourth Edition, Text Revision (DSM-IV) criteria for bipolar I disorder, acute manic or mixed episode
  • Having a total Young Mania Rating Scale (YMRS) score >= 20 and a score of at least 4 on two of the following YMRS items:

    • Irritability,
    • Speech,
    • Content, and
    • Disruptive/Aggressive Behavior

Exclusion criteria

Exclusion Criteria:

  • Patients who exhibit abnormalities on physical examination, have abnormal vital-signs, (ECG), or clinical laboratory values [such as thyroid-stimulating hormone (TSH)].
  • Patients with Montgomery-Åsberg Depression Rating Scale (MADRS) total score >= 18 at Visit 2.
  • Patients experiencing first manic episode.
  • Patients that have received electroconvulsive therapy (ECT) or a depot neuroleptic in the 3 months prior to Visit 1.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    Cariprazine

    Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.

    Drug: Cariprazine (RGH-188)

  • Placebo comparator
    Placebo

    Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.

    Drug: Placebo

Interventions

  • Cariprazine 3 mg - 12 mg oral administration, once per day.

  • DrugPlacebo

    Dose-matched placebo oral administration, once per day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3

    The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a five-point scale (0-4) and 4-items on a nine-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analyses are based on an Analysis of Covariance (ANCOVA) model for change from Baseline with treatment group and study center as factors and Baseline value as covariate.

    Time frame: Baseline, Week 3

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3

    The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7=Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analyses are based on ANCOVA model for change from Baseline with treatment group and study center as factors and Baseline CGI-S score as covariate.

    Time frame: Baseline, 3 Weeks

07

Results

Posted Apr 14, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine
Started120118
Safety population: received study drug118118
Completed7375
Not completed4743
Withdrew: Adverse event1317
Withdrew: Insufficient therapeutic response1811
Withdrew: Protocol violation02
Withdrew: Withdrawal of consent1513
Withdrew: Lost to follow-up10

Outcome measures

PrimaryChange From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3

The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a five-point scale (0-4) and 4-items on a nine-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analyses are based on an Analysis of Covariance (ANCOVA) model for change from Baseline with treatment group and study center as factors and Baseline value as covariate.

Time frame:
Baseline, Week 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3
score on a scalePlaceboCariprazine
Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3-8.91 ± 1.083-15.02 ± 1.078
Statistical analysis
  • Placebo vs Cariprazine · ANCOVA · p = <0.0001 · Least squares mean difference: -6.1 · 95% CI -8.9 to -3.3cariprazine - placebo
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3

The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7=Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analyses are based on ANCOVA model for change from Baseline with treatment group and study center as factors and Baseline CGI-S score as covariate.

Time frame:
Baseline, 3 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3
score on a scalePlaceboCariprazine
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3-0.93 ± 0.125-1.57 ± 0.125
Statistical analysis
  • Placebo vs Cariprazine · ANCOVA · p = 0.0001 · Least squares mean difference: -0.64 · 95% CI -0.97 to -0.32cariprazine - placebo

Adverse events

Collected over First dose of study drug to 30 days past last dose (Up to 51 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/118 (5.1%)73/118 (61.9%)
Cariprazine—7/118 (5.9%)90/118 (76.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboCariprazine
ManiaPsychiatric disorders5/1184/118
ConvulsionNervous system disorders0/1181/118
Extrapyramidal disorderNervous system disorders0/1181/118
DelusionPsychiatric disorders1/1180/118
HypertensionVascular disorders1/1180/118
Deep vein thrombosisVascular disorders0/1181/118
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlaceboCariprazine
Extrapyramidal disorderNervous system disorders13/11829/118
HeadacheNervous system disorders26/11824/118
AkathisiaNervous system disorders8/11823/118
ConstipationGastrointestinal disorders10/11819/118
NauseaGastrointestinal disorders12/11819/118
DyspepsiaGastrointestinal disorders9/11815/118
DizzinessNervous system disorders8/11812/118
VomitingGastrointestinal disorders6/11810/118
InsomniaPsychiatric disorders3/11810/118
AgitationPsychiatric disorders10/1186/118

Baseline characteristics

Safety population included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboCariprazineTotal
Mean38.7 ± 11.038.0 ± 10.338.3 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCariprazineTotal
Female413879
Male7780157
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCariprazineTotal
Hispanic or Latino4610
Not Hispanic or Latino114112226
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazineTotal
Caucasian5547102
Black313667
Asian283058
Other459
Weight
Weight(kilogram (kg))PlaceboCariprazineTotal
Mean79.3 ± 20.075.0 ± 20.377.2 ± 20.2
Height
Height(centimeter (cm))PlaceboCariprazineTotal
Mean170.0 ± 10.4169.9 ± 10.0170.0 ± 10.2
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/meter(m)^2)PlaceboCariprazineTotal
Mean27.2 ± 5.825.8 ± 5.926.5 ± 5.9
08

Study locations

1 site
  • For information regarding investigative sites, contact Forest Professional Affairs
    St. Louis, Missouri 63045, United States
09

References and documents

Publications

  • McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019 Oct 1;257:600-606. doi: 10.1016/j.jad.2019.07.020. Epub 2019 Jul 5. PubMed 31344528 ↗
  • Earley W, Durgam S, Lu K, Ruth A, Nemeth G, Laszlovszky I, Yatham LN. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018 Jan 15;226:239-244. doi: 10.1016/j.jad.2017.09.040. Epub 2017 Sep 25. PubMed 29017067 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 8 years 9 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2007
First posted
Jun 20, 2007
Start
Jun 2007
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results delay requested
Mar 2, 2012
Results first posted
Apr 14, 2017
Last update
Apr 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00488618
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Jun 20, 2007
Start date
Jun 2007
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Apr 14, 2017
Last update
Apr 14, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion